Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Pharma channel feed
What’s the big hurry, Novartis? Pharma giant scores a PRV shortcut for $130M
8 years ago
Boehringer antes up on a €627.5M deal for rights to Autifony’s schizophrenia drugs
8 years ago
Four months after patient death, FDA's hold lifted on Alnylam's fitusiran
8 years ago
Amicus CEO lobbied FDA to reverse FDA’s rejection of migalastat, claiming a delay of up to 7 years
8 years ago
Galapagos snags co-promotion rights on filgotinib — just before Gilead’s lock-up pact expires
8 years ago
R&D
Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs
8 years ago
R&D
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
8 years ago
R&D
Teva axing 14,000 workers, putting R&D and manufacturing facilities on the block in massive restructuring
8 years ago
R&D
Teva sharpens ax, preps brutal cuts in R&D and across the group in face of crushing debt
8 years ago
R&D
When can FDA 'refuse to file' NDAs and BLAs? New draft guidance explains
8 years ago
Allergan buys an ailing Repros, bagging a women’s health drug for the pipeline
8 years ago
Deals
In latest blow to Eli Lilly, Sanofi wins FDA OK for Humalog me-too
8 years ago
Activists threaten to push for a sale of Alexion if execs can't jack up stock price
8 years ago
Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm's tumor invading tech platform
8 years ago
Alexion lines up $40M upfront deal with Halozyme to develop a better, easier next-gen followup to Soliris
8 years ago
Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA
8 years ago
R&D
Cancer R&D tips the scales at the FDA as active INDs climb to record high
8 years ago
R&D
Clinical trial transparency improves at (some) biopharmas as J&J, Sanofi lead a pack trailed by Valeant and Allergan
8 years ago
Merck and PhRMA to FDA: Wait for ICH before finalizing guidance on toxicity testing for cancer drugs
8 years ago
In a blow to Eli Lilly, Novo Nordisk lands FDA OK for their next big entry in the diabetes market: Ozempic
8 years ago
Philippine health officials order Sanofi to halt Dengvaxia sales as controversy over health threat swells
8 years ago
J&J adds PhIII hypertension drug to the pipeline with $230M-plus cash deal for Idorsia
8 years ago
Astellas forges a $390M deal to buy a biotech focused on Ronald Evans’ ‘exercise-in-a-pill’ tech
8 years ago
What's killing patients in Bayer's Xofigo combo study? Researchers unblind study early to probe safety alert
8 years ago
R&D
First page
Previous page
307
308
309
310
311
312
313
Next page
Last page